Market News & Trends
SCHOTT Pharma & KORU Medical Systems Collaborate to Advance Large-Volume Subcutaneous Infusion
SCHOTT Pharma and KORU Medical Systems are joining forces to offer a high volume subcutaneous drug infusion solution…..
First Participants Vaccinated in IMUNON’s Phase 1 Clinical Trial
IMUNON, Inc. recently announced the first participants have been treated in the IMNN-101 Phase 1 clinical trial. This proof-of-concept study of IMUNON’s proprietary PlaCCine platform…
Osteal Therapeutics Closes $5-M Financing to Support Approval & Commercial Launch of Lead Candidate
Osteal Therapeutics, Inc. recently announced the completion of an oversubscribed $50-million Series D preferred stock equity financing. Zimmer Biomet led the round, joined by returning…
Proton Therapy Demonstrates Advantages in Phase 3 Head & Neck Cancer Trial
According to preliminary data from a multi-institution Phase 3 trial led by researchers at The University of Texas MD Anderson Cancer Center, intensity modulated proton…
Wistar Scientists Develop Novel Antibody Treatment for Kidney Cancer
Advanced clear cell renal cell carcinoma (ccRCC) is a deadly form of kidney cancer with few treatment options; even with new immunotherapies, only around one…
ExeVir Bio Announces Exceptional Virus Neutralization Potency of its Variant-Proof Antibody Against the SARS-CoV-2 Variant JN.1
ExeVir Bio recently announced new data demonstrating its antibodies are exceptionally potent in neutralizing the SARS-CoV-2 variant JN.1, the parental strain of the currently most…
Kindeva Drug Delivery Expands Facilities to Support Growth of Green Propellant Commercialization
Kindeva Drug Delivery recently announced the expansion of their Loughborough, UK, facilities at the Charnwood Campus Science Innovation and Technology Park. This strategic move by…
Biolojic Design Enters Multi-Target Drug Discovery Collaboration With Merck KGaA
Merck KGaA, Darmstadt, Germany, will leverage Biolojic Design’s AI capabilities to create potential best-in-class multi-specific antibodies that uniquely modulate biology….
Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients With Tenosynovial Giant Cell Tumor
Deciphera Pharmaceuticals, Inc. recently announced that results from the company’s MOTION pivotal Phase 3 study of vimseltinib in patients with TGCT are being highlighted in…
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies
Denali Therapeutics Inc. recently announced the US FDA has selected DNL126 for participation in the Support for clinical Trials Advancing Rare disease Therapeutics (START) Pilot…
Ecolab Life Sciences & Repligen Announce Commercial Launch of DurA Cycle Affinity Resin for Large-Scale Biologic Manufacturing
St. Paul, MN, US and Waltham, MA, US – June 3, 2024 – Ecolab today announced that its Purolite resin business, together with Repligen Corporation (NASDAQ:RGEN), a life…
Longeveron Announces Contract Development & Manufacturing Business & First Contract
Longeveron Inc. recently announced the launch of its contract development and manufacturing business at the company’s 15,000-sq-ft state-of-the-art Good Manufacturing Practice (GMP) facility. This facility contains….
Aeterna Zentaris & Ceapro Complete Merger Transaction
Aeterna Zentaris Inc. and Ceapro Inc. recently announce the successful completion and closing of their all-stock merger of equals transaction (the Transaction), which was previously announced by….
uniQure Receives FDA Regenerative Medicine Advanced Therapy Designation for Investigational Gene Therapy in Huntington’s Disease
uniQure N.V. recently announced the US FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation for its investigational gene therapy AMT-130 for the treatment of…
PhoreMost Achieves Second Milestone in Target Discovery Alliance With Boehringer Ingelheim
PhoreMost Ltd., has triggered a second milestone payment in its multi-project target discovery collaboration with Boehringer Ingelheim. This was achieved by identifying and validating novel…
Anocca AB & Shinobi Therapeutics Announce Strategic Partnership to Develop Allogeneic TCR-T Cell Therapies in Oncology
Anocca AB and Shinobi Therapeutics recently announced a strategic partnership to use Shinobi’s proprietary immune evasive iPS-T cell platform with novel candidate TCRs, discovered and…
Nxera Pharma & PrecisionLife Expand Strategic R&D Partnership Into New Therapeutic Area
Nxera Pharma Co. Ltd and PrecisionLife recently announced the expansion of their strategic R&D partnership into auto-immune disorders with the potential to identify new drug…
Elevar Therapeutics Reports Landmark Median Overall Survival of 23.8 Months in First-Line Treatment for Unresectable Hepatocellular Carcinoma
Elevar Therapeutics, Inc. recently announced the landmark overall survival (OS) analysis of camrelizumab and rivoceranib as a first-line treatment for unresectable hepatocellular carcinoma (uHCC) will…
Patient Dosing Commenced in Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients With Obstructive Sleep Apnea
Incannex Healthcare Inc. recently announce patient dosing has commenced in the company’s Phase 2/3 clinical trial to assess safety and efficacy of IHL-42X in patients…
Sanofi Completes Acquisition of Inhibrx, Inc.
Sanofi recently announced the completion of its acquisition of Inhibrx, Inc. The acquisition adds SAR447537 (formerly INBRX-101) to Sanofi’s rare disease pipeline, underscoring the company’s…
